Efforts continue in the search for an ideal cycloplegic agent to produce adequate cycloplegia in a relatively short time, rapid recovery from paralysis of accommodation, and no local or systemic ill effects.
Tropicamide (Mydriacyl) is the newest of the cycloplegic agents to be introduced in this country.*
This compound is chemically designated as N-ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide. It is a synthetically prepared derivative of tropic acid and according to the manufacturer, it is a potent mydriatic and cycloplegic compound pharmacologically related to the parasympatholytic group of diagnostic agents. Pharmacological experimental information supplied by the manufacturer states that "studies on the inhibition of the acetylcholine induced blood pressure lowering effect in the dog have shown bistropamide † to possess approximately onehalf the potency of atropine. Its duration of action is, however, considerably shortened." They further stated that irritation studies conducted on animals demonstrated the solution to be devoid of any irritation, and that prolonged
GETTES BC. Tropicamide, a New Cycloplegic Mydriatic. Arch Ophthalmol. 1961;65(5):632–635. doi:10.1001/archopht.1961.01840020634005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: